1133 related articles for article (PubMed ID: 23676348)
1. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D
Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
[TBL] [Abstract][Full Text] [Related]
2. Thrombin generation in antiphospholipid syndrome.
Zuily S; Ait Aissa K; Membre A; Regnault V; Lecompte T; Wahl D
Lupus; 2012 Jun; 21(7):758-60. PubMed ID: 22635224
[TBL] [Abstract][Full Text] [Related]
3. Anti-Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.
Zuily S; de Laat B; Guillemin F; Kelchtermans H; Magy-Bertrand N; Desmurs-Clavel H; Lambert M; Poindron V; de Maistre E; Dufrost V; Risse J; Shums Z; Norman GL; de Groot PG; Lacolley P; Lecompte T; Regnault V; Wahl D
J Appl Lab Med; 2020 Nov; 5(6):1242-1252. PubMed ID: 32572467
[TBL] [Abstract][Full Text] [Related]
4. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
[TBL] [Abstract][Full Text] [Related]
5. Profiling of non-criteria antiphospholipid antibodies in patients with SLE: differentiation of thrombotic SLE patients and risk of recurrence of thrombosis.
Tkachenko O; Lapin S; Mazing A; Emanuel V; Belolipetskaia E; Beliaeva I; Myachikova V; Maslyansky A; Schierack P; Roggenbuck D
Lupus; 2020 Apr; 29(5):490-498. PubMed ID: 32131675
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
[TBL] [Abstract][Full Text] [Related]
7. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
Mustonen P; Lehtonen KV; Javela K; Puurunen M
Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
[TBL] [Abstract][Full Text] [Related]
9. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.
Somers E; Magder LS; Petri M
J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147
[TBL] [Abstract][Full Text] [Related]
10. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
[TBL] [Abstract][Full Text] [Related]
11. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
[TBL] [Abstract][Full Text] [Related]
12. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
[TBL] [Abstract][Full Text] [Related]
13. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
Cabiedes J; Cabral AR; Alarcón-Segovia D
J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
[TBL] [Abstract][Full Text] [Related]
14. [Antiphospholipid thrombosis syndrome and acquired activated protein C resistance].
Wu J; Zhou Z; Li X; Li X; Chen Y; Wang G; Xu X; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 2000 Mar; 21(3):122-4. PubMed ID: 11876968
[TBL] [Abstract][Full Text] [Related]
15. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study.
Stojanovich L; Markovic O; Marisavljevic D; Elezovic I; Ilijevski N; Stanisavljevic N
Lupus; 2012 Mar; 21(3):338-45. PubMed ID: 21993381
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events.
Otomo K; Atsumi T; Amengual O; Fujieda Y; Kato M; Oku K; Horita T; Yasuda S; Koike T
Arthritis Rheum; 2012 Feb; 64(2):504-12. PubMed ID: 21953404
[TBL] [Abstract][Full Text] [Related]
17. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study.
Berube C; Mitchell L; Silverman E; David M; Saint Cyr C; Laxer R; Adams M; Vegh P; Andrew M
Pediatr Res; 1998 Sep; 44(3):351-6. PubMed ID: 9727712
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for arterial thrombosis in antiphospholipid syndrome.
Matyja-Bednarczyk A; Swadźba J; Iwaniec T; Sanak M; Dziedzina S; Ćmiel A; Musiał J
Thromb Res; 2014 Feb; 133(2):173-6. PubMed ID: 24321419
[TBL] [Abstract][Full Text] [Related]
19. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events.
Ho KT; Ahn CW; Alarcón GS; Baethge BA; Tan FK; Roseman J; Bastian HM; Fessler BJ; McGwin G; Vilá LM; Calvo-Alén J; Reveille JD
Rheumatology (Oxford); 2005 Oct; 44(10):1303-7. PubMed ID: 16030085
[TBL] [Abstract][Full Text] [Related]
20. Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus.
Nojima J; Iwatani Y; Ichihara K; Tsuneoka H; Ishikawa T; Yanagihara M; Takano T; Hidaka Y
Thromb Res; 2009 May; 124(1):127-31. PubMed ID: 19128822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
